Weil Richard, Kovacs Betty, Miller Neil, McDermott Michael P, Wall Michael, Kupersmith Mark, Pi-Sunyer F Xavier
Department of Endocrinology, Diabetes and Nutrition Mt Sinai St Luke's Hospital New York NY USA.
Depts of Ophthalmology, Neurology and Neurosurgery Johns Hopkins University School of Medicine Baltimore MD USA.
Obes Sci Pract. 2016 Apr 5;2(2):95-103. doi: 10.1002/osp4.34. eCollection 2016 Jun.
The purpose of this paper is to measure the change in body weight after a 6-month telephone-based weight loss intervention in overweight and obese subjects with idiopathic intracranial hypertension (IIH) and mild visual loss randomized to receive either acetazolamide or placebo.
One hundred sixty-five subjects with IIH, aged 29.1 ± 7.5 (mean ± SD) and BMI 39.9 + 8.3 kg/m, enrolled at 38 academic and private practice sites in North America, participated in this trial. This was a randomized, double-masked, placebo-controlled trial of acetazolamide in subjects with IIH and mild visual loss. All participants received a reduced-sodium, weight-reduction diet and a 6-month telephone-based weight loss intervention. Six-month changes from baseline in body weight, perimetric mean deviation as assessed by automated perimetry and quality of life using the National Eye Institute Visual Function Questionnaire 25 and the 36-item Short Form Health Survey were measured.
Mean percent weight change at 6 months was -5.9% ± 6.7% of initial body weight overall, -3.5% ± 5.9% in the placebo group and -7.8% ± 6.8% in the acetazolamide group. Weight change was not associated with changes in either mean deviation or quality of life scores.
Patients with IIH and mild visual loss assigned to either acetazolamide or placebo, all of whom received a 6-month telephone-based weight loss intervention, lost an average of 5.9% of initial body weight, consistent with NHLBI guidelines of 5% to 10% of body weight loss for clinically significant health benefit.
本文旨在测量超重和肥胖的特发性颅内高压（IIH）且有轻度视力丧失的受试者，在接受为期6个月的基于电话的减肥干预后体重的变化。这些受试者被随机分配接受乙酰唑胺或安慰剂治疗。
165名患有IIH的受试者，年龄为29.1±7.5（平均±标准差），体重指数为39.9 + 8.3kg/m²，在北美的38个学术和私人诊所招募，参与了该试验。这是一项针对患有IIH和轻度视力丧失的受试者的乙酰唑胺随机、双盲、安慰剂对照试验。所有参与者都接受了低钠减肥饮食和为期6个月的基于电话的减肥干预。测量了体重从基线开始的6个月变化、通过自动视野检查评估的视野平均偏差以及使用美国国立眼科研究所视觉功能问卷25和36项简短健康调查问卷评估的生活质量。
总体而言，6个月时平均体重变化百分比为初始体重的-5.9%±6.7%，安慰剂组为-3.5%±5.9%，乙酰唑胺组为-7.8%±6.8%。体重变化与平均偏差或生活质量评分的变化无关。
被分配接受乙酰唑胺或安慰剂治疗的IIH和轻度视力丧失患者，均接受了为期6个月的基于电话的减肥干预，平均体重减轻了初始体重的5.9%，这与美国国立心肺血液研究所（NHLBI）关于体重减轻5%至10%以获得临床显著健康益处的指南一致。
